Get the Stockscreener App
247.08
3.86%
9.19
After Hours:
247.08
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $247.08, with a volume of 1.36M.
It is up +3.86% in the last 24 hours and up +5.41% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$237.89
Open:
$238.39
24h Volume:
1.36M
Relative Volume:
1.44
Market Cap:
$27.27B
Revenue:
$11.28B
Net Income/Loss:
$1.07B
P/E Ratio:
27.25
EPS:
9.0657
Net Cash Flow:
$1.33B
1W Performance:
+4.92%
1M Performance:
+5.41%
6M Performance:
+23.73%
1Y Performance:
+36.80%
1-Day Range:
$237.21
$248.65
1-Week Range:
$228.57
$248.65
52-Week Range:
$171.18
$248.65
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, NTRA, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
247.08 | 25.94B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
641.39 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
209.36 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
350.78 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
269.67 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
150.27 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors - MarketWatch
QUEST DIAGNOSTICS INC : UBS RAISES TARGET PRICE TO $245 FROM $232 - webull.com
Quest Diagnostics Announces Apple Health App Users to Be Able to Order Labs from Quest Diagnostics - marketscreener.com
Apple Health users can buy Quest lab tests for $119 later this year - Stock Titan
UBS raises Quest Diagnostics stock price target on durable volumes By Investing.com - Investing.com Canada
UBS Adjusts Quest Diagnostics Price Target to $245 From $232, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million - Yahoo Finance
Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million - The Motley Fool
Apple Health App to Integrate Quest Diagnostics Testing Services - Intellectia AI
Quest Diagnostics stock edges lower near 52-week highs after solid Q2 growth - ad-hoc-news.de
Quest Diagnostics stock holds steady as investors await next earnings update - ad-hoc-news.de
Man Group takes new $495K stake in Quest Diagnostics as stock nears record high - Dealroom
Quest’s Expanded Alzheimer’s and Wellness Testing Push Might Change The Case For Investing In DGX - Yahoo Finance
CEO of Quest Diagnostics (NYSE: DGX) sells 10,000 shares - Stock Titan
Quest Diagnostics Insider Sold Shares Worth $2,427,200, According to a Recent SEC Filing - marketscreener.com
Quest Diagnostics stock gains as investors focus on growth and fair value - AD HOC NEWS
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics stock trades near 52-week high as kidney testing deal lifts valuation - AD HOC NEWS
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Quest Diagnostics (NYSE: DGX) insider plans new sale after June $1.9M trade - Stock Titan
Quest Diagnostics SVP & general counsel sells $5.5m in shares - Investing.com Nigeria
Quest Diagnostics SVP & general counsel sells $5.5m in shares By Investing.com - Investing.com South Africa
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors - MarketWatch
Quest Diagnostics (DGX) Stock Analysis: Navigating Growth Amidst a Competitive Landscape - DirectorsTalk Interviews
Quest Diagnostics stock holds steady as investors await fresh earnings catalysts - AD HOC NEWS
Quest Diagnostics (NYSE: DGX) holder to sell 22,677 shares - Stock Titan
Humanity Health Inc. And Quest Diagnostics Announce Availability Of Humanity Biological Age Analysis Through questhealth.com - marketscreener.com
Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com - Morningstar
Roche's Alzheimer's blood test gets FDA clearance; Quest plans U.S. launch - stocktitan.net
Quest Diagnostics stock holds near highs after Q2 beat - Ad-hoc-news.de
Is it the Right Time to Retain DGX Stock in Your Portfolio? - TradingView
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Trillium Asset Management LLC Takes $5.43 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
SGL Investment Advisors Inc. Buys Shares of 27,290 Quest Diagnostics Incorporated $DGX - MarketBeat
Danske Bank A S Buys Shares of 68,561 Quest Diagnostics Incorporated $DGX - MarketBeat
5,500 Shares in Quest Diagnostics Incorporated $DGX Acquired by Glaxis Capital Management LLC - MarketBeat
Edmond DE Rothschild Holding S.A. Invests $944,000 in Quest Diagnostics Incorporated $DGX - MarketBeat
Ceredex Value Advisors LLC Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
327,575 Shares in Quest Diagnostics Incorporated $DGX Bought by Advisors Capital Management LLC - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Quest Diagnostics stock extends 2026 rally after Q2 revenue and earnings beat - Ad-hoc-news.de
Tocqueville Asset Management L.P. Takes $22.67 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Wealthfront Advisers LLC Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Deutsche Bank AG Makes New $124.18 Million Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
BlackRock Inc. Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (DGX) Could Be 30% Below Fair Value After Upgrade And WHOOP Deal - finance.yahoo.com
Quest Diagnostics stock hits a fresh high as Q2 earnings beat expectations - Ad-hoc-news.de
Quest Diagnostics stock hits all-time high at 240.15 USD - Investing.com
Quest Diagnostics stock hits all-time high at 240.15 USD By Investing.com - Investing.com Canada
M.D. Sass LLC Buys New Shares in Quest Diagnostics Incorporated $DGX - MarketBeat
Commerzbank Aktiengesellschaft FI Takes $1.42 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):